Pursuant to section 23(1) of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Cathejell Lignocaine 2% gel
Note: This consent is given subject to the following conditions:
- Provisional consent is given subject to the following restriction: The medicine may only be marketed or distributed when no other lignocaine hydrochloride 2% gel with consent to distribute for urethral use is available in the New Zealand market.
Also note: This consent is valid for one year from the date of publication of this notice.
Dated this 25th day of August 2017.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).